Vascular Biosciences is at the forefront of developing innovative medical technologies aimed at improving the diagnosis and treatment of serious vascular diseases. One of their key products is the Endoarterial Biopsy Catheter, which is the first device designed to obtain biopsy samples from the inner layers of arteries in a minimally invasive manner. This technology is expected to significantly enhance the diagnosis and management of vascular diseases, particularly pulmonary arterial hypertension (PAH), by providing detailed pathological profiles of patients' pulmonary arteries. This capability allows for more personalized treatment strategies, as physicians can better understand the specific characteristics of the disease in individual patients.

In addition to their interventional technologies, Vascular Biosciences is advancing targeted therapeutic solutions through their CARSKNKDC (CAR) peptide. This lead therapeutic candidate is designed to selectively target diseased tissues, enhancing the efficacy of co-administered drugs while minimizing systemic side effects. The CAR peptide technology works by binding to specific heparan sulfate residues in the glycocalyx of damaged tissues, facilitating the internalization of therapeutic agents directly into the affected cells. This targeted approach not only aims to improve treatment outcomes for conditions such as pulmonary hypertension, COVID-19, and sepsis but also holds promise for enhancing the effectiveness of various biomedical technologies, including gene therapy and monoclonal antibodies.

United States

Vascular BioSciences (VBS), a biomedical company with operations in Research
Triangle, NC, San Diego, and Goleta, CA, makes interventional catheters
to obtain pulmonary endoarterial biopsies, provides molecular diagnostic
services, and through its majority-owned subsidiary, VBS Pharmaceuticals, 
advances targeted therapies in order to enhance and prolong huma

Vascular Biosciences

Company Details